Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Alimak Group publishes Annual Report for 2018

Alimak Group’s Annual Report 2018, including the sustainability report, has been published on www.alimakgroup.com in Swedish and English.The Annual Report will also be printed in a limited edition and can be ordered from investor@alimakgroup.com. Stockholm, 10 April 2019 Alimak Group AB For further information, please contact:Mathilda Eriksson, Investor Relations Manager, +46 8 402 14 41 This information is information that Alimak Group AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08.00 CET on 10 April

FarmPharma receives EU funding SME instrument Phase I

As previously announced, FarmPharma AB that is subsidiary to Double Bond Pharmaceutical Int. AB, has submitted an application to the European Commission for an SME instrument grant within the framework of the Horizon2020 program, where groundbreaking innovation projects with market-generating potential can be supported. The company funds alone to implement a more in-depth and up to date business plan for continued successful development of InterferOX. The project under the name InFarm has now been funded with the amount of SEK 500,000, which corresponds to the entire sought amount and is

Ambea publishes annual report for 2018 and presents additional information relating to the impact of IFRS 16

Ambea’s annual report for 2018 is published today in pdf-format on ambea.com and is also enclosed to this press release. A printed version will be available for distribution during week 18. In connection to the publication of Ambea’s annual report, Ambea presents updated information relating to the impact of IFRS16 on both Ambea and acquired Aleris Care. A summary is available on ambea.com.

Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer

10 April 2019 07:00 BST Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer AstraZeneca and MSD's Lynparza reduced the risk of disease progression or death by 42% vs. chemotherapy in Phase III OlympiAD trial First PARP inhibitor approved in the EU for patients with this difficult-to-treat disease and third EU approval for Lynparza AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib) as a monotherapy for

Q2: Sharp growth in LCP and SMB affected by temporary effects

Second quarter · Net sales rose 18.1 per cent to SEK 3,215 million (2,723). · Organic growth was 7.8 per cent (1.7), of which SMB accounted for 0.1 per cent (10.9), LCP for 16.1 per cent (neg: 5.0) and B2C for a negative 13.5 per cent (pos: 10.8). · The gross margin rose to 16.3 per cent (15.4). · Adjusted EBITA increased to SEK 154 million (143), corresponding to an adjusted EBITA margin of 4.8 per cent (5.3). · EBIT totalled SEK 160 million (131) including items affecting comparability of SEK 23.2 million (0.3). · Profit for the quarter amounted to SEK 124 million (92).

Water and shore construction skills gained in Finland would also benefit Sweden

YIT CORPORATION News, April 10, 2019 at 09:00 a.m.The key factors behind successful water and shore construction projects are careful planning, special expertise and seamless cooperation. The know-how gleaned from Finnish construction sites can also be exported to other countries, like Sweden, where there is a strong desire to better utilise the valuable shoreline areas. In the near future, the shoreline of important ports located by waterways is going through a change both in Finland and Sweden alike, as old port areas are developed and converted into residential and business areas.

Nanosatellites see the light - laser communication for a new age in space

TESAT, KSAT and GomSpace have partnered up to introduce full optical communications capability for new innovative small satellite missions and space-based services. Until now this technology has mainly been used on large and expensive satellites but is now further developed, miniaturised and ready for use on small satellites and new constellations. The new technology will be launched in the PIXL demonstration mission later in 2019. The benefits of optical communications in space Optical communication technology offers a number of important benefits that will add to the value of

Adjusted comparison figures due to changes in business segments

On 1 March, Handelsbanken carried out a reorganisation which has meant that certain operations in the Handelsbanken Sweden and Handelsbanken Capital Markets business segments have been moved over to Group IT and the newly formed unit Group Products and Services. Income and expenses relating to Group IT and Group Products and Services are reported within Other units. At the same time, the model for the internal capital allocation to the business segments has been adjusted somewhat. Recalculated comparison figures for the past eight quarters are available at http://www.handelsbanken.se/

Additional patent protection for melflufen granted in the US until 2033

Stockholm - 10 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. Oncopeptides has previously received the corresponding patent protection both in Japan and Europe.These patents (application numbers 14/438473 and 15/225323) protect, inter alia, the freeze-dried formulation. The patent protection extends to 2033. The freeze-dried preparation with melflufen is intended to be marketed at a future approval. “We have now approved formulation

MAG Interactive AB (publ) presents interim report Sep – Feb 2018/2019

Multiplayer games show continued revenue growth while user acquisition investments put pressure on the resultComment from CEO in summary “In line with our strategy multiplayer games are now growing steadily and represent about 70% of all revenues, up from less than 50% during the same period last year. Continued investments in performance marketing with good long-term returns, combined with improvements in our multiplayer games is the path back to profitability.”, says Daniel Hasselberg, CEO of MAG. “The negative result this quarter is an effect of user acquisition investments as the

Invitation to Kesko’s Q1/2019 interim report on 25 April 2019

A stock exchange release concerning Kesko Group’s Q1/2019 interim report will be published on Thursday, 25 April 2019, at about 9.00 (EET). Results conference, conducted in Finnish, will be held at 11.00 (EET) in Helsinki, Neptun building, Mannerheimintie 117. Coffee service available at 10.30. Webcast is available at www.kesko.fi/raporttikeskus. A transcript of the Q&A session will be available in English afterwards at www.kesko.fi/report-centre. An audiocast/teleconference, conducted in English, will be held at 14.00 (EET). A link to the audiocast/teleconference is available at www.

Corrected: Immunovia and University College of London sign agreement to expand validation studies of IMMray™ PanCan-d for early signs and symptoms

LUND, SWEDEN - Immunovia today announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London (UCL) will expand the prospective collection of blood samples funded by Immunovia and that started with the PanSYM-1 pilot study.The pilot PanSYM-1 study at UCL that started in 2017 (PR from November 2nd, 2017 ) is scheduled for readout in 2019 and, following today’s news, will now support the continuation of PanSYM-1 as a prospective validation study. The continued PanSYM-1 study

ChloraSolv receives CE marking and is cleared for commercial launch in EU

Gothenburg, Sweden, April 10th, 2019 – RLS Global AB announces that ChloraSolv, its wound care product targeting diabetic foot ulcers, has successfully obtained a CE marking based on confirmation from Lloyd’s Register, acting as Notified Body, and is therefore cleared in 32 European countries for commercialization.ChloraSolv is based on a Swedish innovation, which utilizes RLS Global’s proprietary buffered hypochlorite technology to debride and clean wounds to support the natural wound healing process. Clinical data has shown that ChloraSolv has unique properties with regards to cleansing

Fazer Group commits to cage-free eggs by 2024

Fazer is committed to using only cage-free eggs by 2024 in the Nordic and Baltic countries.Fazer’s commitment to cage-free eggs continues the company’s efforts in line with its sustainability approach and, especially, the core goal of 100% sustainably sourced. In Fazer’s revised sustainability approach, animal welfare was lifted as one of the essential topics, and the commitment to cage-free eggs supports the activities to be taken in this area. The commitment to cage-free eggs covers all Fazer’s businesses and countries of operation but, in the first phase, the focus will be on the Nordic

Aker Solutions and FSubsea to Create FASTSubsea to Boost Subsea Oil Recovery

April 10, 2019 - Aker Solutions and FSubsea have agreed to create FASTSubsea to help operators increase oil recovery in a faster, simpler and more environmentally friendly way. Multiphase subsea pumping technology has the potential to increase oil recovery rates by more than 20 percent, but cost, space limitations and sometimes complex solutions mean multiphase pumps are installed in fewer than 30 of the world's 1,500+ offshore fields. With FASTSubsea, this is about to change. The new company combines Aker Solutions' high-performance multiphase hydraulic technology with FSubsea's game-

Publishing of Valmet's Interim Review January - March 2019 on April 26, 2019

Valmet Oyj's press release on April 10, 2019 at 9:00 a.m. EET Valmet's Interim Review for January - March 2019 will be published on Friday, April 26, 2019 at approximately 9:00 a.m. Finnish time (EET). The stock exchange release and presentation material in Finnish and in English will be available at that time on Valmet's website at www.valmet.com/investors. News conference for analysts, investors and media Valmet will arrange a news conference in English for investment analysts, investors, and media on Friday, April 26, 2019 at 1:00 p.m. Finnish time (EET). The news conference

Diet rich in animal protein is associated with a greater risk of death

A diet rich in animal protein and meat in particular is not good for the health, a new study from the University of Eastern Finland finds, providing further backing for earlier research evidence. Men who favoured animal protein over plant-based protein in their diet had a greater risk of death in a 20-year follow-up than men whose diet was more balanced in terms of their sources of protein. The findings were published in the American Journal of Clinical Nutrition. Men whose primary sources of protein were animal-based had a 23% higher risk of death during the follow-up than men who had

The nomination committee´s proposal for the Board of Directors of SSM Holding

The nomination committee of SSM Holding AB (publ) proposes re-election of board members Anders Janson, Bo Andersson, Per Berggren, Sheila Florell, Ulf Morelius, Ulf Sjöstrand and Jonas Wikström. The nomination committee’s other proposals regarding remuneration, audit company etc. will be made public in the notice to the annual general meeting of SSM. The nomination committee’s statement to the annual general meeting 2019 will be made public on SSM’s corporate website no later than in connection with the notice. The nomination committee’s members are Johannes Wingborg (committee chair)

The road to registration in the US clarified

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the US Food and Drug Administration (FDA) during a pre-IND meeting is positive about the combination registration of IsoConDa and AnaConDa in the US. Sedana Medical now has a clear view of measures that have to be taken in order to reach marketing authorization approval of both IsoConDa and AnaConDa in the US. The meeting also confirmed Sedana Medical's estimate of the time and cost of a US approval that is expected to occur in 2024."The FDA has set clear requirements that are in line with the expectations we had, and they

New board members invest SEK 9.6 million in Brighter through a directed share issue.

IT entrepreneur and tech investor Emanuel Lipschütz and blockchain profile Tove Andersson, both of which have been proposed as new board members in Brighter for the Annual General Meeting in 2019, invest SEK 9.6 million through a directed share issue. Tove Andersson invests SEK 70,000 which is equivalent to the first year's board remuneration in Brighter. Tove Andersson is a prominent blockchain profile, founder of KryptoGäris, Scandinavia's largest crypto and blockchain network for women, and currently CMO of the blockchain company Superblocks. Emanuel Lipschütz invests SEK 9.5

DFDS offer passengers fast broadband from Nowhere Networks

The shipping company DFDS has chosen Swedish Nowhere Networks as its strategic supplier of fast broadband on all the six vessels operating the Dover-Calais and Dover-Dunkerque routes.After having successfully evaluated Nowhere Networks’ complete Wireless Antenna Tracking Solution DFDS has decided to proceed with a full rollout on all its ships operating the heavily trafficked routes in the English Channel. – Our evaluation has yielded impressive results which makes us highly confident in signing a strategic partnership with Nowhere Networks as our supplier of a fast-broadband capability.

Change in Management and Board of Directors.

The Nomination Committee of Brighter AB has proposed Truls Sjöstedt as new Chairperson of the Board and will endorse the proposal at the Annual General Meeting 2019. Truls is currently the company's CEO. The Board of Directors intends to appoint Henrik Norström, today COO, as CEO in connection with the Annual General Meeting on May 9. “During the last 12 years I have built and run the company. With the completion of Actiste, Brighter is facing a major commercial shift entering a new phase characterized by new challenges. I look forward to continuing to drive the company's top-level

Official notification of the annual general meeting.

Brighter AB (publ) will hold its Annual General Meeting (AGM) on Thursday 9th of May, at 11:00, at the offices of Brighter AB, Norgegatan 2 in Kista, Sweden. RIGHT TO PARTICIPATE AND REGISTRATION  Those who wish to participate in the Meeting must:  · Be registered as a shareholder in the shareholder register maintained by Euroclear Sweden AB by Friday 3rd of May 2019 and, · Inform the company of their intent to participate in the Meeting by Friday 3rd of May 2019 at the latest. Registration of participation must be made in writing to – preferably – ir@brighter.se, or by

Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

Oslo, Norway, 10 April 2019 Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation (SCT) has now reviewed safety data from the first three cohorts of patients. Based on the data, the SRC approved advancing the trial to the next and final cohort with the dose regimen 20 MBq/kg Betalutin and a lilotomab pre-dose of 100 mg/m2. The

There are no items matching the current filter
There are no more items matching the current filter
Back to top